Gene: OPCML

4978
IGLON1|OBCAM|OPCM
OD binding protein/cell adhesion molecule like
protein-coding
11q25
Ensembl:ENSG00000183715 MIM:600632 Vega:OTTHUMG00000163658 UniprotKB:Q14982
NG_012107.1
SNP Mapped
6   ANCO-SNPs
ND|AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.375e-1 (AD)  4.040e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs10894669chr11:133337045 (GRCh38.p7)C>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs4379857chr11:133313709 (GRCh38.p7)G>A / G>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs1941220chr11:133284546 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs11223321chr11:133013102 (GRCh38.p7)A>Calcohol dependenceSNV(Single Nucleotide Variation)
rs1793257chr11:132714224 (GRCh38.p7)C>A / C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs4936173chr11:132622531 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg20941739chr11:133035052OPCMLGene body6.863e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AMPH0.972
NELL20.97
CDK140.97
PAK10.97
DLGAP10.968
PRKCE0.968
CREG20.967
HECW10.967
AAK10.967
SV2B0.966

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.564
LRAT-0.541
RAB13-0.53
YES1-0.528
REST-0.522
CHST14-0.52
RHOD-0.516
RAI14-0.513
SYDE1-0.511
RNF135-0.51

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in decreased expression of OPCML mRNA"20206263
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of OPCML mRNA28943387
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of OPCML mRNA21298039
D001151ArsenicArsenic affects the methylation of OPCML gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of OPCML mRNA20458559
C015001arsenitearsenite results in increased methylation of OPCML promoter23974009
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of OPCML mRNA21839799
C006780bisphenol Abisphenol A results in decreased expression of OPCML mRNA26364221
C006780bisphenol Abisphenol A affects the expression of OPCML mRNA21786754
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in decreased expression of OPCML mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of OPCML mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of OPCML mRNA27571134
D000068579CelecoxibCelecoxib results in increased expression of OPCML mRNA28201806
D013759Dronabinol[Dronabinol co-treated with Ethanol] results in increased expression of OPCML mRNA17618662
D013759DronabinolDronabinol results in increased expression of OPCML mRNA17618662
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of OPCML mRNA21266533
D004008DiclofenacDiclofenac results in increased expression of OPCML mRNA26934552
D004054DiethylstilbestrolDiethylstilbestrol results in decreased expression of OPCML mRNA25242112
C118739entinostatentinostat results in decreased expression of OPCML mRNA27188386
C118739entinostatentinostat results in increased expression of OPCML mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
D000431Ethanol[Dronabinol co-treated with Ethanol] results in increased expression of OPCML mRNA17618662
D000431EthanolEthanol results in increased expression of OPCML mRNA17618662
D005419FlavonoidsFlavonoids results in increased expression of OPCML mRNA18035473
C069837fullerene C60fullerene C60 results in decreased expression of OPCML mRNA19167457
D007213IndomethacinIndomethacin results in increased expression of OPCML mRNA28201806
D007213IndomethacinIndomethacin results in decreased expression of OPCML mRNA25972201
D007854LeadLead affects the expression of OPCML mRNA28903495
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of OPCML mRNA26011545
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of OPCML mRNA"20188158
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OPCML mRNA27935865
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of OPCML mRNA27935865
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of OPCML mRNA26272509
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of OPCML mRNA"25510870
D010575PesticidesPesticides results in increased methylation of OPCML gene28396702
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of OPCML mRNA27935865
D011441PropylthiouracilPropylthiouracil results in decreased expression of OPCML mRNA24780913
C017947sodium arsenitesodium arsenite affects the methylation of OPCML gene28589171
D013739Testosterone[bisphenol A co-treated with Testosterone] results in decreased expression of OPCML mRNA26496021
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of OPCML mRNA24680724
C009495titanium dioxidetitanium dioxide results in increased expression of OPCML mRNA19695317
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased methylation of OPCML promoter25214829
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of OPCML mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of OPCML mRNA23179753|2519280
D014635Valproic AcidValproic Acid results in increased expression of OPCML mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of OPCML gene29154799
C025643vinclozolinvinclozolin affects the expression of OPCML mRNA19015723
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OPCML mRNA"27188386
C111237vorinostatvorinostat results in decreased expression of OPCML mRNA27188386
C111237vorinostatvorinostat results in increased expression of OPCML mRNA26272509
C581157XL147[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of OPCML mRNA27935865
D015034Zinc OxideZinc Oxide analog results in decreased expression of OPCML mRNA27215404

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0007155cell adhesion-IEA-  
GO:0008038neuron recognition-TAS7891157  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005886plasma membrane-TAS-  
GO:0031225anchored component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-163125Post-translational modification: synthesis of GPI-anchored proteinsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal